The Business Of Neurotech

Adam Fraser

From breakthrough devices to the bottom line. The Business of Neurotech is the premier podcast dedicated to the commercial trends, investment strategies, and innovative business models shaping the neuroscience economy. Hosted by Adam Fraser, this series moves beyond the lab to explore how groundbreaking research in neuromodulation, BCI, and medical devices is transformed into viable, scalable enterprises. +2 Each episode features candid, fireside-chat interviews with the ecosystem's most influential voices—from founders and CEOs to venture capitalists and strategic leaders. We dive into the "how" and "why" behind the headlines, discussing market maturity, regulatory hurdles, and the go-to-market strategies required to bring neurotechnology to the global stage. +3 Whether you are an investor conducting due diligence, a researcher exploring commercial applications, or an entrepreneur building the next generation of brain-tech, this show provides the strategic insights you need to navigate the future of the sector.

Episodes

  1. 3d ago

    Matt Angle Talks Paradromics and BCI Market Dynamics

    For people who have lost the ability to speak, brain-computer interfaces (BCIs) could open a new path back to communication. In this episode, Adam Fraser speaks with Matt Angle, founder and CEO of Paradromics, about the company’s 11-year journey to build a BCI that can restore communication for people who have lost it. Matt explains why moving more neural data is central to BCI performance and how Paradromics is approaching safety, durability and clinical translation. He breaks down why speech restoration is the company’s first clinical focus, then unpacks what could come next, including movement applications, mood biomarkers and AI-enabled communication. The conversation also explores the company’s move from Silicon Valley to Austin, Texas, as well as the regulatory, reimbursement, funding and commercial realities of building in deep tech, and what it takes to turn frontier neuroscience into a durable company. Listen in for a closer look at Paradromics’ journey and the technology, capital and strategic thinking shaping the future of BCI. Key Points From This Episode: [01:31] Discover how Matt’s neuroscience background led him to found Paradromics.[03:18] Learn how BCI has shifted from pure science to an engineering challenge.[04:53] Hear why Matt has stayed in the CEO role 11 years into the journey.[07:34] Understand Paradromics’ focus on safety, durability and neural data.[08:29] Why moving more neural data is central to building better BCI systems.[14:00] Learn why speech restoration is Paradromics’ first clinical focus.[15:20] Explore the broader medical applications Paradromics may pursue next.[20:11] Find out why Paradromics moved from Silicon Valley to Austin, Texas.[22:25] Matt’s perspective on FDA engagement, regulation and reimbursement pathways.[27:26] Explore how Paradromics thinks about funding, competition and investor alignment.[33:28] Hear Matt’s view on IPO potential and the wider BCI ecosystem.[35:18] Why “invasive” is not always the best way to assess BCI risk.[39:29] Matt’s advice for founders building deep tech companies. Links Mentioned in Today’s Episode: Derrick Matthew Buchanan on LinkedIn Canada Neuro Royal World Archive Derrick Buchanan, Ph.D. Clinical Neuroscience  ‘The complex landscape of TMS devices: A brief overview’ ‘A visual and narrative timeline of US FDA milestones for Transcranial Magnetic Stimulation (TMS) devices’ ‘Should rTMS be considered a first-line treatment for major depressive episodes in adults?’ ‘Stanford neuromodulation therapy for treatment-resistant depression: a randomized controlled trial confirming efficacy, and an EEG study providing insight into mechanism of action and a potentially predictive biomarker of efficacy’ ‘Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression’ Matt Angle on LinkedIn Paradromics Paradromics | Connexus Matt Angle on Substack ‘CMS and FDA Announce RAPID Coverage Pathway to Accelerate Patient Access to Life-Changing Medical Devices’ Adam Fraser on LinkedIn Omniscient Neurotechnology The Business of Neurotech Podcast

  2. Aug 24

    Derrick Buchanan talks Stanford, Transcranial Magnetic Stimulation and Neurotech

    Brain stimulation is moving from specialist clinics towards faster, more personalised and scalable care. In this episode, Adam Fraser speaks with Dr Derrick Buchanan, a clinical neuroscientist in Stanford’s Brain Stimulation Lab, entrepreneur, author and speaker whose work spans precision brain imaging, neuromodulation and mental health. Derrick discusses his path from Canada to Stanford and explores how the university turns research into companies. He unpacks how transcranial magnetic stimulation works, why adoption still lags behind its clinical promise, and where portable devices may take the field. They also explore the neurotech ecosystem and the long-term investment logic behind BCI. Tune in to hear how science, commercialisation and access could shape the next generation of brain care with Dr Derrick Buchanan. Key Points From This Episode: [01:50] Discover how Dr Buchanan’s career path shaped his work and entrepreneurship.[09:22] Explore what makes Stanford the ideal place for cutting-edge research.[11:56] Unpack how Stanford handles IP, licensing and startup ownership.[16:16] Learn how transcranial magnetic stimulation (TMS) stimulates the brain.[23:30] Uncover the barriers holding back the wider adoption of TMS.[28:29] Find out how portable TMS could expand access and when to expect it.[31:09] Hear his perspective on applying neurotech across imaging, stimulation and BCI.[34:28] Dr Buchanan explains how invasive and non-invasive tools can coexist.[38:31] Final takeaways and why investors are betting heavily on BCI.Links Mentioned in Today’s Episode: Derrick Buchanan  Derrick Buchanan on X Stanford Medicine The Brain Stimulation Lab (BSL)  Canadian Institutes of Health Research Stanford Office of Technology Licensing Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) Motif Neurotech Episode 6: David Eagleman Talks Media, Startups, and Neuroscience Episode 4: Mariam Khayretdinova talks EEG, AI and Psychiatry Adam Fraser on LinkedIn  Omniscient Neurotechnology  The Business of Neurotech Podcast

  3. Aug 10

    Matias Serebrinsky talks frontier brain and mental health VC investing

    What makes an emerging technology bold enough and a founder exceptional enough to justify taking an early-stage risk? In this episode of The Business of Neurotech, Adam Fraser sits down with Matias Serebrinsky, Founding Partner at PsyMed Ventures, a specialist venture capital fund investing in frontier brain and mental health technologies. Matias brings a dual perspective as both a former startup founder and an early-stage investor who previously supported AI companies during a pivotal period in the industry’s growth. In this conversation, he reflects on how breakthrough technologies move from research labs into real-world products and what it takes for scientific drive to become a venture-scale company. They also discuss the evolution of neurotechnology as an investment category, the realities of backing high-risk frontier science, and how PsyMed assesses early-stage opportunities across brain-computer interfaces, neuromodulation, mental health innovation and more. Tune in for an investor’s view of the people and technologies driving frontier neuro forward. Key Points From This Episode: [01:15] Explore Matias’ journey from startup founder and NVIDIA to neuro investing.[05:37] Uncover the three qualities PsyMed looks for in an early-stage investment.[06:54] Explore Matias’ broad definition of neurotech and the market behind it.[08:30] He shares PsyMed’s approach to investing early and supporting founders.[12:55] Whether specialist and generalist funds will grow as more investors join.[15:35] Consider what major exits could mean for neurotech’s investment appeal.[18:54] Learn which opportunities are currently capturing PsyMed’s attention.[22:18] Hear about a BCI company taking a different path to developing neurotech.[28:34] Discover the role capital plays in turning science into a successful company.[30:58] Unpack the different hardware approaches to neuromodulation. [34:15] Understand what changes when a wellness product enters medical territory.[36:28] Matias’ advice for researchers considering the startup journey.Links Mentioned in Today’s Episode: Matias Serebrinsky on LinkedIn PsyMed Ventures PsyMed Ventures on Substack Business Trip Podcast ‘The State of Frontier Neuro’ Motif Adam Fraser on LinkedIn  Omniscient Neurotechnology  The Business of Neurotech Podcast

  4. Jul 27

    Richard Mulry Talks Health System Venture Capital and Neurotech Investing

    How do you turn promising neurotechnology into solutions that can actually work inside healthcare systems? In this episode of The Business of Neurotech Podcast, Adam Fraser is joined by Richard Mulry, President and CEO of Northwell Holdings, the for-profit venture investment arm of Northwell Health, to explore what it takes to identify, invest in, and scale innovation in clinical care. Richard explains why Northwell prefers to invest in companies it would use itself, and how clinical evidence, workflow integration, and strong partnerships shape every investment decision. The conversation explores the unique opportunities and challenges of neurotechnology, from brain-computer interfaces (BCIs) and neurorehabilitation to AI-enabled platforms and bioelectronic medicine. Richard also shares why solving meaningful clinical problems matters more than following investment trends, how strategic healthcare investors can help companies prove real-world value, and what founders should know about working with strategic investors. Listen in for an insightful discussion on what it takes to bring neurotechnology from concept to clinical impact! Key Points From This Episode: [01:28] Richard’s career in healthcare and his path to Northwell Holdings.[04:32] Background on Northwell and its approach to healthcare innovation.[07:15] Discover Northwell's investment process and selection criteria.[11:25] Why Northwell prefers to invest in companies it would use itself.[12:30] Find out how Northwell complements traditional venture capital investors.[16:46] Understand Richard’s perspective on the neurotech market.[19:29] Hear why Northwell invested in Cognixion and its evolving platform.[21:43] Explore Northwell’s view of invasive versus non-invasive BCIs.[26:36] Learn about Northwell’s latest neurotech investments.[31:31] Understand how Northwell supports companies through FDA and reimbursement.[32:50] Discover how AI is reshaping healthcare operations and medtech.[37:03] Richard’s advice for founders seeking strategic investors.[39:33] Final takeaways and how to connect with Northwell Holdings.Links Mentioned in Today’s Episode: Richard Mulry on LinkedIn Northwell Holdings Northwell Holdings on LinkedIn Northwell Health Northwell Health on LinkedIn Feinstein Institutes for Medical Research | Northwell Health Cognixion Neuvotion Spark Biomedical OhmBody SetPoint Medical Adam Fraser on LinkedIn Omniscient Neurotechnology The Business of Neurotech Podcast

  5. Jul 13

    Nicolas Vachicouras Talks BCI Market Dynamics and Start Up Life

    What does it take to build a BCI company around better hardware, stronger data, and a long-term view of how the brain will be decoded? In this episode of The Business of Neurotech, host Adam Fraser is joined by Nicolas Vachicouras, CEO and co-founder of Neurosoft Bioelectronics, to discuss his path from microelectronics and nanotechnology into the BCI space, and how Neurosoft is developing soft, stretchable electrodes designed to sit on the brain surface rather than penetrate it. Adam and Nicolas discuss the technical and commercial thinking behind Neurosoft’s strategy, how the company has moved from early academic work to first-in-human studies, and why platform thinking now matters more than pursuing a single indication. They also discuss fundraising in Europe versus the US, why BCI still needs high-quality invasive data to unlock future breakthroughs, how the partnership with Science Corp fits into the wider BCI value chain, and why Nicolas believes the field will likely support several major players over time. Tune in now! Key Points From This Episode: [01:25] Nicolas’ backstory and how his studies led him into BCI.[03:17] See how Nicolas first started thinking about commercialising neurotechnology.[05:56] Explore what Neurosoft is building and the core idea behind its approach to BCI.[07:43] Understand how Neurosoft’s approach differs from typical BCI technology.[09:17] The different levels of invasiveness in BCI and how this impacts data quality.[11:38] Neurosoft’s progress and how the roadmap to clinical trials is taking shape.[15:15] Learn how Neurosoft’s focus has evolved from tinnitus towards a broader strategy.[17:40] Find out whether mental health is part of Neurosoft’s long-term plan.[18:52] Unpack Neurosoft’s funding journey and what Nicolas has learnt along the way.[21:19] Discover why Neurosoft is starting with the US market, instead of Europe.[22:28] Why funding in a market where competitors have more capital is not an issue.[24:00] Examine how the partnership with Science Corp fits into Neurosoft’s long-term goals.[28:27] How BCI fits into the broader neurotech ecosystem and the future market of BCI.[30:59] Uncover why reimbursement remains such an important challenge for BCI.[32:39] Hear how Nicolas thinks about building a team for a long-term goal. [36:14] Final takeaways and how to connect with Nicolas and Neurosoft Bioelectronics.Links Mentioned in Today’s Episode: Nicolas Vachicouras Nicolas Vachicouras on LinkedIn Neurosoft Bioelectronics Science Corp Adam Fraser on LinkedIn Omniscient Neurotechnology The Business of Neurotech Podcast

  6. Jun 29

    Ryan Field Talks Kernel and Neuroscience as a Service

    What does it take to build a brain measurement company from the ground up and turn neuroscience into a scalable service? In this episode of The Business of Neurotech, host Adam Fraser is joined by Ryan Field, CEO of Kernel, to talk about what it means to build brain technology in an emerging market. Adam and Ryan discuss Ryan’s path from electrical engineering and sensing technology into neurotech, and how Kernel has evolved from an early invasive BCI vision into a company focused on non-invasive brain measurement. They also explore how Kernel is building a platform across different applications, the company’s funding journey, the promise and limits of invasive BCI and why whole-brain measurement may matter more than many investors currently realise. Tune in for a look at Kernel’s strategy and the broader business logic shaping the next phase of neurotech. Key Points From This Episode: [01:10] Discover Ryan’s backstory and how his career led him into neurotech.[04:44] How his interest in engineering and biology pulled him towards the brain.[06:30] What made neurotech feel like an emerging space when he joined Kernel.[07:22] Understand Kernel’s original vision and how the company has evolved.[12:25] Why Kernel is focused on becoming a foundational measurement layer for the brain.[13:22] Find out about Bryan Johnson’s role at Kernel and how he has shaped its direction.[16:34] How Ryan sees his role in Kernel and why it feels like more than a typical CEO job.[18:10] Unpack Kernel’s funding journey and why Bryan’s backing was so important.[20:19] Learn why the brain represents a major risk for investors in neurotech.[21:20] Examine how Kernel is turning neuroscience into a scalable service for customers.[24:01] Kernel’s approach to commercialising across research, longevity and wellness.[27:28] Uncover how Kernel is working with pharma and aiding drug development.[30:07] Hear Ryan’s view on the recent surge in funding for invasive BCI companies.[33:43] Whether neurotech is heading toward a few big winners or many niche companies.[36:24] Final takeaways and advice on how to keep a team aligned and motivated.Links Mentioned in Today’s Episode: Ryan Field on LinkedIn Kernel Bryan Johnson on LinkedIn ‘A compact time-domain diffuse optical tomography system for cortical neuroimaging’ Blueprint Adam Fraser on LinkedIn  Omniscient Neurotechnology  The Business of Neurotech Podcast

  7. Jun 15

    David Eagleman Talks Media, Startups, and Neuroscience

    How do you turn neuroscience ideas into real businesses without losing sight of the science? In this episode of The Business of Neurotech, host Adam Fraser sits down with neuroscientist, author, podcaster, entrepreneur, and Stanford educator David Eagleman to explore his journey across academia and neurotech startups. David discusses how he shifted from running a traditional neuroscience lab to building ventures in sensory substitution, digital cognitive assessment, and companion robotics, and delves into what he has learned about markets, investors, regulation, and founder decision-making along the way. Adam and David also discuss why some neurotech ideas struggle to find the right market, the balance between wellness and regulated health technology, and why the next wave of BCI may go beyond metal electrodes. Tune in to hear David’s take on building in neurotech, where the field is heading, and what it really takes to turn big ideas into lasting companies. Key Points From This Episode: [01:28] Discover David’s backstory, what he is doing today, and how he divides his time.[03:53] How investors view backing David as a founder with the many commitments he has.[04:58] Hear how David decides where to invest his time across neuroscience and neurotech.[07:02] Learn what Neosensory was built to do and the thinking behind sensory substitution.[10:00] Find out if Neosensory was ahead of its time and about the market hurdles it faced.[13:45] Explore his opinion on non-invasive neurotech versus invasive brain interfaces.[15:04] What BrainCheck solved and how it became a digital cognitive assessment platform.[19:00] Uncover what Jojo Health is building and what got him into companion robotics.[24:40] Unpack the main commercial themes across David’s different neurotech ventures.[27:33] David shares what he has learned about fundraising, venture capital, and regulation.[31:00] Understand how David made the jump from academia into startup life.[33:35] Advice for new neurotech founders and what they should take into consideration. [37:41] Insights into where neurotech is heading next and how to connect with David. Links Mentioned in Today’s Episode: David Eagleman David Eagleman on X David Eagleman on Facebook David Eagleman on Instagram David Eagleman on LinkedIn David Eagleman on TikTok David Eagleman on Bluesky Inner Cosmos Podcast Stanford University BrainCheck Jojo Health  Science Corporation Subsense Adam Fraser on LinkedIn Omniscient Neurotechnology The Business of Neurotech Podcast

  8. Jun 1

    Naveen Rao Talks Neurotech Market Dynamics

    Where is neurotech money really flowing, and what do the numbers say about where the industry is heading next? In this episode of The Business of Neurotech, host Adam Fraser sits down with Naveen Rao, founder of Patchwise Labs, curator of Neurotech Futures, and Forbes contributor covering neurotechnology’s impact on business and society. In their conversation, Naveen shares how a career spanning public health, health policy, advocacy, and healthcare analysis led him into neurotech and explains why he now sees the field as one of the most important and fast-moving frontiers in healthcare. Adam and Naveen unpack how he defines the sector, what stood out in his 2025 funding analysis, and why brain-computer interfaces continue to attract so much capital. They also discuss where other momentum is building across neuromodulation and consumer neurotech, and how artificial intelligence is shaping both the companies being built and the capital flowing into them. Tune in for a look at the aspects shaping neurotech now and in the future. Key Points From This Episode: [01:20] How Naveen’s background led him to neurotech and founding Patchwise Labs. [04:43] Learn about his goal with Neurotech Futures and how it fits within Patchwise Labs.[08:42] Hear why Naveen sees Substack as a strong platform for writers.[09:41] Explore how he defines the neurotech space, and he sees it as a mixed space.[11:27] Find out how he keeps up with the latest neurotech news and developments. [13:50] Unpack the main takeaways from Naveen’s 2025 neurotech funding snapshot.[17:09] Why brain-computer interfaces (BCI) continue to attract a large share of funding.[20:54] Understand why BCI may be seen as the ultimate platform play in neurotech.[22:34] Naveen highlights the latest tech trends and news in neurotech.[25:44] The line between consumer neurotech and regulated medical devices.[27:54] Discover what the 2025 funding data suggests about the top neurotech sectors.[30:03] Whether the AI funding boom could affect capital available for neurotech.[34:41] His opinion on the potential of neurotech becoming a standalone investment category.[38:38] Uncover the potential impact of a major neurotech IPO on the mobilisation of capital.[40:37] Final takeaways and how to connect with Naveen. Links Mentioned in Today’s Episode: Naveen Rao on LinkedIn Neurotech Futures Forbes Patchwise Labs ‘2025 Neurotech Funding Snapshot’ The Focused Ultrasound Foundation Newsletter SetPoint Medical Surf Therapeutics NeuroPace Adam Fraser on LinkedIn Omniscient Neurotechnology The Business of Neurotech Podcast

  9. May 18

    Mariam Khayretdinova talks EEG, AI and Psychiatry

    What if the future of psychiatry depended less on subjective questionnaires and more on biological data, scalable brain models, and artificial intelligence? In this episode of The Business of Neurotech, host Adam Fraser sits down with Mariam Khayretdinova, Founder and CEO of Brainify.AI, a company building electroencephalography (EEG) foundation models for precision neuroscience. Mariam brings a mix of applied mathematics, technology, psychology, and lived experience to the discussion, drawing from her own mental health journey and her work at Brainify.AI. In their conversation, Mariam shares how she went from Russia to tech consulting and eventually into neuroscience entrepreneurship. She explains why psychiatry remains so difficult to diagnose and treat objectively, how small and inconsistent datasets limit progress, and why EEG offers a scalable starting point for building brain-based models. Adam and Mariam also explore Brainify.AI’s go-to-market strategy, its work with pharma companies, the funding realities neurotech founders face, and the future of AI-enabled psychiatry. They also delve into Mariam’s book, Decoding Despair: How AI is Reshaping Psychiatry, and her vision for a world where mental health care is more data-driven and free from stigma. Tune in to learn how EEG, AI, and foundation models could help reshape the future of psychiatry, clinical trials, and mental health care with Mariam Khayretdinova. Key Points From This Episode: [01:22] Discover how Mariam moved from applied mathematics into neuroscience.[03:12] How her experience at Harvard helped her with research and critical thinking.[06:35] Explore how Mariam’s experiences with depression sparked her interest in psychiatry.[09:43] Hear about the origin story behind Brainify.AI and its overall aim for mental health.[14:06] Learn why Mariam chose EEG as Brainify.AI’s primary data source.[15:56] Brainify.AI’s approach to supporting biomarker discovery and treatment prediction.[21:37] Examine Brainify.AI’s go-to-market strategy in pharma, model access, and data.[24:12] Whether brain foundation models could become the base layer for future applications.[24:57] Find out how Mariam manages focus across Brainify.AI’s many possible use cases.[27:03] Uncover the harsh realities of raising funds as a neurotech founder.[31:32] Why Mariam wrote Decoding Despair and what she hopes to achieve with the book.[34:24] Understand how AI could support earlier detection and personalised mental health care.Links Mentioned in Today’s Episode: Mariam Khayretdinova Mariam Khayretdinova on LinkedIn Brainify.AI Decoding Despair: How AI is Reshaping Psychiatry Adam Fraser on LinkedIn  Omniscient Neurotechnology  The Business of Neurotech Podcast

  10. May 4

    Amy Kruse Talks Venture Investing in Neurotech

    What does it take to turn cutting-edge brain science into real-world impact? In this episode of The Business of Neurotech Podcast, host Adam Fraser is joined by Dr Amy Kruse, General Partner and CIO (Chief Investment Officer) at Satori Neuro, whose career spans neuroscience research, DARPA (Defense Advanced Research Projects Agency) program leadership, and venture investing. Dr Kruse shares how her early work in human performance and neurotechnology revealed both the promise and the limitations of emerging tools, and why commercialisation became a key driver of progress. The conversation explores the evolution of the neurotech sector, from early, hardware-heavy systems to today’s ecosystem of scalable platforms, data-driven insights, and investment opportunities. Dr Kruse offers a clear-eyed view on what it takes to build successful neurotech companies, from focusing on core technical breakthroughs to aligning science with commercial milestones. She also discusses the shift toward precision treatment and the long-term potential of technologies that can both treat and prevent neurological challenges. Listen in to hear Dr Amy Kruse’s perspective on where neurotech is heading next! Key Points From This Episode: [00:16] Dr Amy Kruse’s journey from neuroscience research and DARPA to Satori Neuro.[03:52] How these experiences led Dr Kruse to focus on commercialising neurotechnology.[05:49] Barriers to early neurotech adoption, including hardware limitations.[08:13] Lessons from DARPA on combining technical progress with commercial milestones.[10:05] Defining neurotechnology, the brain capital economy, and emerging market terms.[13:34] The growing role of specialist investors and rising capital in neurotech.[17:32] Overview of Satori Neuro’s investment approach and focus areas.[20:03] The role of precision neuroscience and the move toward personalised treatment.[23:09] Dr Kruse’s current approach to treatment and prevention in neurotech investing.[25:04] The rise of consumer neurotech and growing interest in personal brain data.[27:55] Dr Kruse’s preference for platform technologies over single-outcome investments.[30:01] What she looks for in founders, including self-awareness and coachability.[34:21] How the potential of Brain-computer interfaces (BCIs) is driving investment and future applications.[40:02] Where to follow Dr Amy Kruse’s work, including her newsletter and Satori Neuro. Links Mentioned in Today’s Episode: Amy Kruse Amy Kruse on LinkedIn Satori Capital Satori Neuro Sign up to the Satori Neuro Newsletter Adam Fraser on LinkedIn Omniscient Neurotechnology The Business of Neurotech Podcast

  11. Apr 27

    Keith Murphy Talks Focused Ultrasound and Start-Up Life

    Can focused ultrasound finally make deep brain stimulation scalable, non-invasive, and practical for everyday patients? In this episode of The Business of Neurotech, host Adam Fraser sits down with Keith Murphy, co-founder and CTO of Attune Neurosciences, to explore how his path from behavioural neuroscience and optogenetics led to a company building wearable focused ultrasound technology for brain stimulation. Keith explains how Attune is tackling the commercial limits of clinic-based neuromodulation, why portability and at-home treatment matter, and how the company is balancing scientific ambition with startup realities like reimbursement, product design, indication focus, and fundraising. They also dig into Attune’s early work in chronic pain and obsessive-compulsive disorder, the broader promise of neurotechnology across mental health and neurology, and how artificial intelligence is changing both product development and the investment landscape. Tune in for a sharp look at what it takes to turn frontier neurotechnology into a real business with Keith Murphy. Key Points From This Episode: [01:04] Learn how Keith’s background led him to found Attune Neurosciences.[04:54] Hear how he began thinking about translating his science into a scalable company.[06:38] Find out how he balances being a scientist with running a company.[08:50] How focused ultrasound compares with transcranial magnetic stimulation (TMS).[12:52] Discover why Attune is focused on building a prescribed at-home medical device.[13:58] Understand how Attune’s wearable works and why it is less intimidating for patients. [15:41] Why chronic pain and obsessive-compulsive disorder are effective early indicators.[20:02] Whether psychiatry forms part of Attune’s long-term neurotechnology roadmap.[22:38] Uncover Attune’s funding journey so far and its path toward a Series A round.[26:28] Unpack the opportunities and challenges of the neurotech market. [29:08] How fundraising has helped refine Attune’s strategy, product, and approach.[31:15] Explore how AI is driving software development while creating more challenges.[35:20] Keith shares how to connect with him and learn more about Attune.  Links Mentioned in Today’s Episode: Keith Murphy on LinkedIn Attune Neurosciences fus Forward Podcast The Scripps Research Institute Stanford University Rajiv Mahadevan on LinkedIn Amy Kruse on LinkedIn Genoa Ventures Adam Fraser on LinkedIn Omniscient Neurotechnology The Business of Neurotech Podcast

  12. Apr 22

    Michael Brotherton Talks Neurotech Market Dynamics and Neurotech Investing

    What does it really take to turn neurotechnology into a scalable business? In this episode of The Business of Neurotech, host Adam Fraser sits down with Michael Brotherton, co-founder and managing partner at Dragonfly 44, to explore the capital, strategy, and market forces shaping the sector. Michael talks about his journey from science into investment banking and how this ultimately led him to establish a business specialising in neuroscience and neurotechnology. He then delves into his definition of neuroscience and neurotech across devices, diagnostics, therapeutics, BCI, and digital tools. Adam and Michael also dig into the surge of investor interest in brain-computer interfaces, the growing overlap between neurotech, biomarkers, and AI, and why clinician networks and community-driven investing could become a real edge as the market matures. Tune in for a look at where neurotech is heading and what it may take to build lasting companies in the space with Michael Brotherton! Key Points From This Episode: [00:58] Background about Michael and what led him to focus on neurotech. [05:11] What type of expertise is needed to work in the neurotech space.[07:21] Learn what neurotech is and what makes it stand out from other sectors.[11:03] Find out why defining the size and scope of the neurotech market is still difficult.[13:30] Explore what is driving such strong investor interest in brain-computer interfaces.[15:12] Michael’s take on the most compelling neurotech subsectors today.[17:02] Discover how Dragonfly 44 approaches servicing the neurotech market.[19:10] What makes neurotech corporate finance different from medtech.[21:37] Hear why building a venture fund was always part of Michael’s long-term vision.[22:50] Unpack how AI could reshape investing, capital raising, and networking.[29:04] How AI may lower startup capital requirements and open up more opportunities.[30:21] Understand how Michael is thinking about his funding and networking efforts.[34:16] Final comments and how to connect with Michael to learn more about his work. Links Mentioned in Today’s Episode: Michael Brotherton on LinkedIn Dragonfly 44 Capital D44 Ventures Neuroscience News Adam Fraser on LinkedIn Omniscient Neurotechnology

  • 12 Episodes

Ratings & Reviews

5
out of 5
2 Ratings

About

From breakthrough devices to the bottom line. The Business of Neurotech is the premier podcast dedicated to the commercial trends, investment strategies, and innovative business models shaping the neuroscience economy. Hosted by Adam Fraser, this series moves beyond the lab to explore how groundbreaking research in neuromodulation, BCI, and medical devices is transformed into viable, scalable enterprises. +2 Each episode features candid, fireside-chat interviews with the ecosystem's most influential voices—from founders and CEOs to venture capitalists and strategic leaders. We dive into the "how" and "why" behind the headlines, discussing market maturity, regulatory hurdles, and the go-to-market strategies required to bring neurotechnology to the global stage. +3 Whether you are an investor conducting due diligence, a researcher exploring commercial applications, or an entrepreneur building the next generation of brain-tech, this show provides the strategic insights you need to navigate the future of the sector.

Information

  • Creator
    Adam Fraser
  • Years Active
    2026
  • Episodes
    12
  • Rating
    Clean
  • Copyright
    © 2026 Copyright 2026 - The Business of Neurotech
  • Show Website
    The Business Of Neurotech

You Might Also Like